tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Dermatomycoses D003881 17 associated lipids
Dermatomyositis D003882 2 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diarrhea D003967 32 associated lipids
Digestive System Diseases D004066 3 associated lipids
Down Syndrome D004314 18 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Dyspnea D004417 10 associated lipids
Earache D004433 2 associated lipids
Echinostomiasis D004451 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Eczema D004485 4 associated lipids
Edema D004487 152 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Epididymitis D004823 1 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Erythema D004890 22 associated lipids
Erythema Nodosum D004893 5 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Erythroplasia D004919 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Exanthema D005076 11 associated lipids
Eye Diseases D005128 12 associated lipids
Facial Dermatoses D005148 7 associated lipids
Facial Neoplasms D005153 3 associated lipids
Fatigue D005221 10 associated lipids
Fatty Liver D005234 48 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Folliculitis D005499 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Foot Dermatoses D005533 3 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Lemmens HP et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. 1994 Transplant. Proc. pmid:7527983
Mueller AR et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. 1994 Transplant. Proc. pmid:7527984
Tanabe M et al. The influence of donor and recipient strains in isolated small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7527986
Yamamoto S and Kato R Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. 1994 J. Dermatol. Sci. pmid:7528050
Rao US and Scarborough GA Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. 1994 Mol. Pharmacol. pmid:7514263
Lieberman DN and Mody I Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. 1994 Nature pmid:7514273
Burdmann EA et al. Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. 1994 Ren Fail pmid:7514309
Jindal RM et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. 1994 Transplantation pmid:7514317
Eng WK et al. The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. 1994 Gene pmid:7530227
Petros AM and Fesik SW Nuclear magnetic resonance methods for studying protein-ligand complexes. 1994 Meth. Enzymol. pmid:7530321
Klintmalm GB FK 506: an update. 1994 Clin Transplant pmid:7517226
Dawson TM et al. The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. 1994 Neuroscience pmid:7530348
Curley RW et al. Stereospecific assignments of glycine in proteins by stereospecific deuteration and 15N labeling. 1994 J. Biomol. NMR pmid:7517241
Nagase K et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. 1994 J. Pharm. Pharmacol. pmid:7517447
Glaum SR and Miller RJ Inhibition of phosphoprotein phosphatases blocks metabotropic glutamate receptor effects in the rat nucleus tractus solitarii. 1994 Mol. Pharmacol. pmid:7517497
Tanaka K et al. Living related liver transplantation in children. 1994 Am. J. Surg. pmid:7517649
Singh N et al. Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506? 1994 Dig. Dis. Sci. pmid:7506641
Lee TK et al. Bacterial translocation and the role of postoperative selective bowel decontamination in small intestinal transplantation. 1994 Transplant. Proc. pmid:7518154
Grossi P et al. Infectious complications in experimental small bowel transplantation. 1994 Transplant. Proc. pmid:7518155
D'Ambrosio R et al. Improved procedures for enzyme immunoassay of tacrolimus (FK506) in whole blood. 1994 Clin. Chem. pmid:7507007
Bäckman L et al. Chronic nephrotoxicity of FK 506 after liver transplantation. 1994 Transplant. Proc. pmid:7518159
Bäckman L et al. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. 1994 Transplant. Proc. pmid:7518160
Logan TM et al. Structural characterization of the FK506 binding protein unfolded in urea and guanidine hydrochloride. 1994 J. Mol. Biol. pmid:7508991
Cooper MH et al. Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. 1994 Transplantation pmid:7509089
Rosh JR et al. Therapy with FK 506 in pediatric liver recipients. 1994 Transplant. Proc. pmid:7509091
Yamamoto S et al. Inhibition of anthralin-caused skin tumor promotion and interleukin-1 alpha production by potent immunosuppressant FK506. 1994 Cancer Lett. pmid:7520353
Scantlebury VP et al. Pediatric kidney transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7509095
Enslen H and Soderling TR Roles of calmodulin-dependent protein kinases and phosphatase in calcium-dependent transcription of immediate early genes. 1994 J. Biol. Chem. pmid:7520433
Sewell TJ et al. Inhibition of calcineurin by a novel FK-506-binding protein. 1994 J. Biol. Chem. pmid:7520438
Oyanagui Y Nitric oxide- and hydrogen peroxide-mediated gene expression by glucocorticoids and FK506 in histamine paw edema of mice. 1994 Life Sci. pmid:7520521
Gonschior AK et al. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). 1994 Br J Clin Pharmacol pmid:7534100
Malyszko J et al. FK 506 affects platelet aggregation in vitro. 1994 Thromb. Res. pmid:7521072
Schreier MH Immunophilins and immunosuppression by cyclosporins and macrolide structures. 1994 Acta Derm Venereol Suppl (Stockh) pmid:7521103
Chen Y et al. A putative sirolimus (rapamycin) effector protein. 1994 Biochem. Biophys. Res. Commun. pmid:7521160
Tsuchida M et al. Effects of irradiation, glucocorticoid and FK506 on cell-surface antigen expression by rat thymocytes: a three-colour flow cytofluorometric analysis. 1994 Immunology pmid:7530693
Meadows RP et al. A computer-based protocol for semiautomated assignments and 3D structure determination of proteins. 1994 J. Biomol. NMR pmid:7510556
Shapiro R et al. Improving results of pediatric renal transplantation. 1994 J. Am. Coll. Surg. pmid:7522851
Moia LJ et al. Immunosuppressants and calcineurin inhibitors, cyclosporin A and FK506, reversibly inhibit epileptogenesis in amygdaloid kindled rat. 1994 Brain Res. pmid:7522929
Pai SY et al. Cross-linking CD28 leads to activation of 70-kDa S6 kinase. 1994 Eur. J. Immunol. pmid:7523138
Schmidt B et al. A homodimer represents an active species of the peptidyl-prolyl cis/trans isomerase FKBP25mem from Legionella pneumophila. 1994 FEBS Lett. pmid:7523184
Tacrolimus introduced for use in liver transplantation. 1994 Am J Hosp Pharm pmid:7524317
Przepiorka D et al. Blood tacrolimus concentration unchanged by plasmapheresis. 1994 Am J Hosp Pharm pmid:7524318
Burnett D et al. Inhibition by FK506 of formyl peptide-induced neutrophil activation and associated protein synthesis. 1994 Biochem. Pharmacol. pmid:7524504
Bierer BE Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action. 1994 Chem. Immunol. pmid:7524531
Lepre CA et al. Solution structure of FK506 bound to the R42K, H87V double mutant of FKBP-12. 1994 Biochemistry pmid:7524662
Winkler M et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression. 1994 Clin. Chem. pmid:7527306
Platz KP et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. 1994 Transpl. Int. pmid:11271297
Lewis HM Therapeutic progress. II: Treatment of psoriasis. 1994 J Clin Pharm Ther pmid:7527403
Metcalfe S et al. FK 506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fluxes. 1994 Transpl. Int. pmid:11271304
Chen SR et al. Asymmetrical blockade of the Ca2+ release channel (ryanodine receptor) by 12-kDa FK506 binding protein. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7527548
Moutabarrik A et al. Effect of immunosuppressive agents FK 506 and cyclosporin and steroids on the expression of IL-6 and its receptor by stimulated lymphocytes and monocytes. 1994 Transpl. Int. pmid:11271305
Calmus Y [Rejection of a liver allograft. Diagnosis and treatment]. 1994 Ann Radiol (Paris) pmid:7527621
Winkler M et al. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. 1994 Transpl. Int. pmid:11271312
Okubo Y et al. Cytokine production in patients with mite-sensitive bronchial asthma. 1994 Int. Arch. Allergy Immunol. pmid:7512395
Jiang H et al. The superior effect of the combination of FK 506 and deoxyspergualin on rat cardiac allograft survival. 1994 Transpl. Int. pmid:7527637
Devlin J et al. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group. 1994 Transpl. Int. pmid:11271328
Wilson JR et al. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. 1994 Muscle Nerve pmid:7512691
Lyons WE et al. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7512727
Lhoëst G et al. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. 1993 Sep-Oct Drug Metab. Dispos. pmid:7694828
Iwasaki K et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. 1993 Nov-Dec Drug Metab. Dispos. pmid:7507815
Fukuse T et al. Combined therapy with FK-506 and cyclosporine for canine lung allotransplantation: immunosuppressive effects and blood trough levels. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508750
Morris RE New small molecule immunosuppressants for transplantation: review of essential concepts. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508752
Schreier MH Immunophilins and immunosuppression. 1993 Mar-Apr Clin. Exp. Rheumatol. pmid:7686830
Piekoszewski W et al. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. 1993 Jul-Aug Drug Metab. Dispos. pmid:7690698
Kobayashi J et al. A new rat infection-heart transplant model: effect of infection on graft survival studies. 1993 Jul-Aug J. Heart Lung Transplant. pmid:7690253
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Zeevi A et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. 1993 Transplant. Proc. pmid:7679843
Reese JC et al. The effect of FK506 on canine bile flow. 1993 Transplantation pmid:7504342
Woodle ES et al. FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. 1993 Transplantation pmid:7504346
Jindal RM et al. Effect of deoxyspergualin on the endocrine function of the rat pancreas. 1993 Transplantation pmid:7504347
Nishinaka Y et al. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. 1993 J. Cardiovasc. Pharmacol. pmid:7681507
Luan S et al. Immunosuppressants implicate protein phosphatase regulation of K+ channels in guard cells. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7681590
Doi R et al. Structural and functional changes of exocrine pancreas induced by FK506 in rats. 1993 Gastroenterology pmid:7681795
Simek SL et al. Sequence and localization of a novel FK506-binding protein to mouse chromosome 11. 1993 Genomics pmid:7507077
Quesniaux VF Immunosuppressants: tools to investigate the physiological role of cytokines. 1993 Bioessays pmid:7507316
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Storb R et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. 1993 Transplantation pmid:7692635
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Sato M et al. FK506 inhibits phytohemagglutinin-, but not interferon-gamma-, induced HLA-DR antigen expression and accessory cell function on primary cultured human thyroid cells. 1993 Acta Endocrinol. pmid:7509103
Clipstone NA and Crabtree GR Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. 1993 Ann. N. Y. Acad. Sci. pmid:7509131
Takahara S Efficacy of FK506 in renal transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7509132
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Denesyuk AI et al. Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems. 1993 Biochem. Biophys. Res. Commun. pmid:7683466
Waschulewski IH et al. Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. 1993 Br. J. Pharmacol. pmid:7683567
Ohtake M et al. Enhanced liver regeneration in rats treated with 15-deoxyspergualin alone and in combination with FK 506. 1993 Gastroenterol. Jpn. pmid:7683616
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Li W and Handschumacher RE Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. 1993 J. Biol. Chem. pmid:7686148
Wong PY et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. 1993 J. Hepatol. pmid:7686192
Henke W and Jung K Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria. 1993 Biochem. Pharmacol. pmid:7690566
Jacobs JC et al. Pyoderma gangrenosum in infancy. 1993 J. Am. Acad. Dermatol. pmid:7688775
Garrity GM et al. Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and rapamycin. 1993 J. Ind. Microbiol. pmid:7688970
Hoof T et al. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. 1993 Eur. J. Pharmacol. pmid:7689059
Lieberman R FK506, artificial intelligence and pharmacoeconomics. 1993 J Clin Pharmacol pmid:7690045
McMichael J et al. An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. 1993 J Clin Pharmacol pmid:7690046
Jain AB et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. 1993 J Clin Pharmacol pmid:7690047
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526
Uemoto S et al. Experience with FK506 in living-related liver transplantation. 1993 Transplantation pmid:7679528
Talento A et al. A single administration of LFA-1 antibody confers prolonged allograft survival. 1993 Transplantation pmid:7679531